Clinical Trials
Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide
Astellas Pharma Inc and Pfizer Inc announced the amendment of the protocol for the registrational PROSPER trial, a multi-national, randomized, double-blind, placebo-controlled study evaluating...
Packaging & Labelling
Bosch launches a pilot fermenter for manufacturing APIs
Bosch has launched a new pilot fermenter for the cultivation of active pharmaceutical ingredients (APIs) on laboratory and pilot scale. “In the pharmaceutical industry, the...
Press Releases
Vitafoods Asia 2017: Spotlight on Finished Products
At the upcoming edition of Vitafoods Asia in Singapore, Asia Pacific’s nutraceutical industry will gather at the annual event to do business, uncover the...
News
TraceLink Unveils Automated Validation Manager, Removes Burden of Validating Software Updates for Life Sciences Cloud Customers
TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and eliminating counterfeit prescription drugs from the global...
Press Releases
TraceLink unveils industry’s first Compliance and Digital Information Platform for pharmacies with EU FMD requirements
TraceLink Inc., the world’s largest track and trace network for connecting the life sciences supply chain and providing real-time information sharing for better patient...
News
Priorclave Appoints New CEO for its American Operation
Leading British autoclave specialist Priorclave is delighted to announce their appointment of Barbra Wells as President and CEO to head up its American operation....
Drug Research
Eisai Enters Into Joint Research Agreement With The Broad Institute To Develop An Antimalarial Medicine
Eisai Co Ltd announced that it has entered into a new joint research agreement with the Broad Institute , a collaborative research institute which...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read